Αποτελέσματα Αναζήτησης
19 Ιουν 2023 · All participants received 18 weeks of chemotherapy with paclitaxel 80 mg/m 2 IV once weekly and non-pegylated liposomal doxorubicin 20 mg/m 2 IV once weekly. Patients with TNBC received simultaneous bevacizumab 15 mg/kg IV once every 3 weeks.
29 Μαΐ 2024 · The treatment landscape for early-stage TNBC has changed considerably in the last decade, with new additions to neoadjuvant therapy (NAT) aimed at improving pathologic responses and outcomes. In this study, we assess real world data regarding treatment and outcomes in those with early-stage TNBC.
15 Φεβ 2023 · Rapid clearance of ctDNA during neoadjuvant chemotherapy in early TNBC is associated with a high probability of achieving pCR [76]. In contrast, the detection of ctDNA after completion of neoadjuvant chemotherapy and surgery is associated with a higher rate of recurrence and a poorer prognosis [77].
29 Μαΐ 2020 · In the adaptive neoadjuvant phase II I-SPY 2 trial, the AKT inhibitor MK-2206 plus standard neoadjuvant chemotherapy of weekly paclitaxel followed by AC achieved an estimated pCR rate of 40% when compared with 22% from chemotherapy alone in the TNBC subgroup . These results support further evaluation of AKT inhibition + paclitaxel and AC ...
9 Νοε 2021 · Tumour heterogeneity and a long-standing paucity of effective therapies other than chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype with the least...
14 Αυγ 2024 · The study aimed to assess the effectiveness and safety of dose-dense AC compared to every 3-week AC in patients with early-stage TNBC undergoing neoadjuvant chemotherapy plus pembrolizumab.
29 Οκτ 2019 · NACT is associated with increased rate of pathologic complete response (pCR), which has been associated with reduced risk of death and recurrence in all subtypes, including TNBC. 3 Residual cancer burden (RCB) after NACT has also been shown to predict disease recurrence and survival across all subtypes. 8 Additionally, neoadjuvant treatment ...
